Arcturus Therapeutics Holdings, Inc. (ARCT)
10.34
-0.93
(-8.25%)
USD |
NASDAQ |
Oct 16, 16:00
10.23
-0.11
(-1.06%)
After-Hours: 20:00
Arcturus Therapeutics Holdings Research and Development Expense (Annual) : 96.10M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 96.10M |
| December 31, 2024 | 124.69M |
| December 31, 2023 | 109.03M |
| December 31, 2022 | 142.55M |
| December 31, 2021 | 168.66M |
| December 31, 2020 | 66.55M |
| December 31, 2019 | 33.64M |
| December 31, 2018 | 16.98M |
| Date | Value |
|---|---|
| December 31, 2017 | 15.92M |
| December 31, 2016 | 17.93M |
| December 31, 2015 | 13.46M |
| December 31, 2014 | 25.10M |
| December 31, 2013 | 7.066M |
| December 31, 2012 | 0.818M |
| December 31, 2011 | 1.822M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 328.80M |
| Emergent BioSolutions, Inc. | 53.80M |
| Exelixis, Inc. | 825.00M |
| Ionis Pharmaceuticals, Inc. | 913.18M |
| United Therapeutics Corp. | 550.00M |